HeartSciences Inc. (NASDAQ:HSCS) Sees Significant Increase in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 41,615 shares, an increase of 36.3% from the January 15th total of 30,531 shares. Based on an average daily volume of 35,393 shares, the short-interest ratio is presently 1.2 days. Currently, 1.3% of the company’s stock are short sold. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 35,393 shares, the short-interest ratio is presently 1.2 days.

HeartSciences Stock Performance

Shares of NASDAQ:HSCS traded down $0.12 during midday trading on Monday, hitting $3.00. 5,137 shares of the company’s stock traded hands, compared to its average volume of 27,279. HeartSciences has a twelve month low of $2.01 and a twelve month high of $6.47. The firm’s fifty day moving average price is $2.99 and its two-hundred day moving average price is $3.17. The company has a market cap of $9.54 million, a PE ratio of -0.44 and a beta of 2.51.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, December 15th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.05. The business had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities research analysts anticipate that HeartSciences will post -10.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HSCS shares. Ascendiant Capital Markets lifted their target price on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.20.

Institutional Investors Weigh In On HeartSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new stake in shares of HeartSciences during the 2nd quarter worth $43,000. TFB Advisors LLC purchased a new position in HeartSciences in the third quarter valued at about $105,000. Finally, DRW Securities LLC raised its holdings in shares of HeartSciences by 13.7% during the 4th quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock valued at $294,000 after purchasing an additional 11,455 shares in the last quarter. Institutional investors own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.